TrialCancer medicine2026
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.
Joyce O'Shaughnessy et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papertrialcites it
TrialCancer medicine2026
Joyce O'Shaughnessy et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.